home
Number
Title
Author
Date
19
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENT IN ITS APATINIB-NIVOLUMAB COMBINATION STUDY
admin
1970.01.01
18
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENTS IN THE US AND EUROPE FOR ITS ONGOING APATINIB PHASE 3 CLINICAL TRIAL IN ADVANCE
admin
1970.01.01
17
LSKB ANNOUNCES ITS CLINICAL INITIATIVE TO STUDY THE SAFETY AND EFFICACY OF COMBINING APATINIB WITH IMMUNOTHERAPY
admin
1970.01.01
16
LSKB ANNOUNCES COMPLETION OF ENROLLMENT FOR THE ANGEL STUDY OF RIVOCERANIB (APATINIB) IN GASTRIC CANCER
admin
1970.01.01
15
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL CLINICAL COLLABORATION TO EVALUATE THE COMBINATION OF ANTI-ANGIOGENE
admin
1970.01.01
14
LSKB ANNOUNCES MFDS APPROVAL TO INITIATE A PHASE I/IIA COMBINATION STUDY OF RIVOCERANIB AND PACLITAXEL AT ASAN MEDICAL CENTER (
admin
1970.01.01
13
LSKB ANNOUNCES THAT ENROLLMENT HAS OPENED AT HUNTSMAN CANCER INSTITUTE FOR THE APPEASE STUDY COMBINING RIVOCERANIB AND PEMBROLI
admin
1970.01.01
12
HLB Co., Ltd. launches multipurpose High-Speed Rescue Boat
admin
1970.01.01
11
LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer
admin
1970.01.01
10
Apatinib, designated as European orphan drug..'Speeding' licensing-out to market
admin
1970.01.01